76 related articles for article (PubMed ID: 38577613)
21.
Zhu G; Shi R; Li Y; Zhang Z; Xu S; Chen C; Cao P; Zhang H; Liu M; Pan Z; Liu H; Chen J
Front Immunol; 2021; 12():670040. PubMed ID: 34512623
[TBL] [Abstract][Full Text] [Related]
22. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
23. Lung metastases share common immune features regardless of primary tumor origin.
García-Mulero S; Alonso MH; Pardo J; Santos C; Sanjuan X; Salazar R; Moreno V; Piulats JM; Sanz-Pamplona R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591432
[TBL] [Abstract][Full Text] [Related]
24. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
[TBL] [Abstract][Full Text] [Related]
25. The SWI/SNF complex in cancer - biology, biomarkers and therapy.
Mittal P; Roberts CWM
Nat Rev Clin Oncol; 2020 Jul; 17(7):435-448. PubMed ID: 32303701
[TBL] [Abstract][Full Text] [Related]
26. Autoimmune complications of immunotherapy: pathophysiology and management.
Chan KK; Bass AR
BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
[TBL] [Abstract][Full Text] [Related]
27. Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity.
Schadt L; Sparano C; Schweiger NA; Silina K; Cecconi V; Lucchiari G; Yagita H; Guggisberg E; Saba S; Nascakova Z; Barchet W; van den Broek M
Cell Rep; 2019 Oct; 29(5):1236-1248.e7. PubMed ID: 31665636
[TBL] [Abstract][Full Text] [Related]
28. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.
Finotello F; Mayer C; Plattner C; Laschober G; Rieder D; Hackl H; Krogsdam A; Loncova Z; Posch W; Wilflingseder D; Sopper S; Ijsselsteijn M; Brouwer TP; Johnson D; Xu Y; Wang Y; Sanders ME; Estrada MV; Ericsson-Gonzalez P; Charoentong P; Balko J; de Miranda NFDCC; Trajanoski Z
Genome Med; 2019 May; 11(1):34. PubMed ID: 31126321
[TBL] [Abstract][Full Text] [Related]
29. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
[TBL] [Abstract][Full Text] [Related]
30. [Report of cancer epidemiology in China, 2015].
Zheng RS; Sun KX; Zhang SW; Zeng HM; Zou XN; Chen R; Gu XY; Wei WW; He J
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):19-28. PubMed ID: 30678413
[No Abstract] [Full Text] [Related]
31. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
[TBL] [Abstract][Full Text] [Related]
32. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM; Lee CH; Shoushtari AN; Hellmann MD; Shen R; Janjigian YY; Barron DA; Zehir A; Jordan EJ; Omuro A; Kaley TJ; Kendall SM; Motzer RJ; Hakimi AA; Voss MH; Russo P; Rosenberg J; Iyer G; Bochner BH; Bajorin DF; Al-Ahmadie HA; Chaft JE; Rudin CM; Riely GJ; Baxi S; Ho AL; Wong RJ; Pfister DG; Wolchok JD; Barker CA; Gutin PH; Brennan CW; Tabar V; Mellinghoff IK; DeAngelis LM; Ariyan CE; Lee N; Tap WD; Gounder MM; D'Angelo SP; Saltz L; Stadler ZK; Scher HI; Baselga J; Razavi P; Klebanoff CA; Yaeger R; Segal NH; Ku GY; DeMatteo RP; Ladanyi M; Rizvi NA; Berger MF; Riaz N; Solit DB; Chan TA; Morris LGT
Nat Genet; 2019 Feb; 51(2):202-206. PubMed ID: 30643254
[TBL] [Abstract][Full Text] [Related]
33. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
34. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Nathanson T; Rizvi H; Creelan BC; Sanchez-Vega F; Ahuja A; Ni A; Novik JB; Mangarin LMB; Abu-Akeel M; Liu C; Sauter JL; Rekhtman N; Chang E; Callahan MK; Chaft JE; Voss MH; Tenet M; Li XM; Covello K; Renninger A; Vitazka P; Geese WJ; Borghaei H; Rudin CM; Antonia SJ; Swanton C; Hammerbacher J; Merghoub T; McGranahan N; Snyder A; Wolchok JD
Cancer Cell; 2018 May; 33(5):843-852.e4. PubMed ID: 29657128
[TBL] [Abstract][Full Text] [Related]
35. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Hoadley KA; Yau C; Hinoue T; Wolf DM; Lazar AJ; Drill E; Shen R; Taylor AM; Cherniack AD; Thorsson V; Akbani R; Bowlby R; Wong CK; Wiznerowicz M; Sanchez-Vega F; Robertson AG; Schneider BG; Lawrence MS; Noushmehr H; Malta TM; ; Stuart JM; Benz CC; Laird PW
Cell; 2018 Apr; 173(2):291-304.e6. PubMed ID: 29625048
[TBL] [Abstract][Full Text] [Related]
36. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
[TBL] [Abstract][Full Text] [Related]
37. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Miao D; Margolis CA; Gao W; Voss MH; Li W; Martini DJ; Norton C; Bossé D; Wankowicz SM; Cullen D; Horak C; Wind-Rotolo M; Tracy A; Giannakis M; Hodi FS; Drake CG; Ball MW; Allaf ME; Snyder A; Hellmann MD; Ho T; Motzer RJ; Signoretti S; Kaelin WG; Choueiri TK; Van Allen EM
Science; 2018 Feb; 359(6377):801-806. PubMed ID: 29301960
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.
Racle J; de Jonge K; Baumgaertner P; Speiser DE; Gfeller D
Elife; 2017 Nov; 6():. PubMed ID: 29130882
[TBL] [Abstract][Full Text] [Related]
39. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
Charoentong P; Finotello F; Angelova M; Mayer C; Efremova M; Rieder D; Hackl H; Trajanoski Z
Cell Rep; 2017 Jan; 18(1):248-262. PubMed ID: 28052254
[TBL] [Abstract][Full Text] [Related]
40. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.
Becht E; Giraldo NA; Lacroix L; Buttard B; Elarouci N; Petitprez F; Selves J; Laurent-Puig P; Sautès-Fridman C; Fridman WH; de Reyniès A
Genome Biol; 2016 Oct; 17(1):218. PubMed ID: 27765066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
